Is a liver enzyme increase expected with long term tigecycline?

Is liver enzyme increase expected with long term tigecycline?

Tigecycline is a glycylcycline antibiotic approved for complicated skin infections, intra-abdominal infections, and community-acquired pneumonia. It blocks protein synthesis in bacteria by binding to the 30S ribosomal subunit.

Liver enzyme increases occur in clinical trials, but they are usually mild and reversible upon discontinuation.

What liver enzyme changes occur in patients taking tigecycline?

Tigecycline causes mild transaminase elevations in 1.7–5.4% of patients in Phase 3 trials. ALT and AST rise early in treatment, but rarely meet criteria for Hy’s Law cases or progress to severe hepatitis. Data from the prescribing information and adverse-event databases show that the pattern is hepatocellular rather than cholestatic.

How long does the effect persist after stopping tigecycline?

Most elevations resolve within two to weeks after stopping the drug. Persistent or progressive elevation beyond that time suggests an alternative cause.

Can long-term tigecycline use lead to serious liver injury?

No cases of acute liver failure, chronic liver disease, or death attributable to tigecycline have been reported in the FDA adverse-event database or literature. Risk appears low, but long-term exposure data remain limited.

What factors increase risk of liver enzyme rise with tigecycline?

Pre-existing liver disease, concomitant hepatotoxic drugs, or high-dose regimens increase likelihood of elevation. Patients with Child-Pugh class B or C should receive 25 mg twice daily rather than the 50 mg dose.

When does the patent for tigecycline expire?

Tigecycline’s composition-of-matter patent expired in 2018. Generic versions entered the U.S. market in 2020.